ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding ImmunityBio, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 147 | 1 | 118 | −28 |
| Shares | 46.2M | 163.9K | 39.1M | −6.93M (−15.0%) |
| Value | $84.1M | $298.4K | $108.7M | +$24.9M (+29.7%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held ImmunityBio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Exchange Traded Concepts, LLC | 47,540 | $132.2K | 0.00% |
| Kestra Advisory Services, LLC | 26,700 | $74.2K | 0.00% |
| Jump Financial, LLC | 22,635 | $62.9K | 0.00% |
| Ameriprise Financial Inc | 22,400 | $62.3K | 0.00% |
| Western Wealth Management, LLC | 20,795 | $57.8K | 0.00% |
| The PNC Financial Services Group, Inc. | 20,100 | $55.9K | 0.00% |
| Bell & Brown Wealth Advisors, LLC | 20,100 | $55.9K | 0.03% |
| Bard Financial Services, Inc. | 19,250 | $53.5K | 0.00% |
| Man Group plc | 10,242 | $28.5K | 0.00% |
| Grimes & Company, Inc. | 10,000 | $27.8K | 0.00% |
| Ascent Wealth Partners, LLC | 10,000 | $27.8K | 0.00% |
| Endurance Wealth Management, Inc. | 10,000 | $22.0K | 0.00% |
| Lazard Asset Management LLC | 5,899 | $16.0K | 0.00% |
| Steward Partners Investment Advisory, LLC | 400 | $1.11K | 0.00% |
| Parallax Volatility Advisers, L.P. | 297 | $826 | 0.00% |
| Sofos Investments, Inc. | 3 | $26 | 0.00% |
Sold out (44)
Institutions that held ImmunityBio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (1)
Institutions that held ImmunityBio, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| ETF Managers Group, LLC | 163,948 | $298.4K |